hOX40

系統名

C57BL/6Smoc-Tnfrsf4em1(hTNFRSF4)Smoc

SMOC番号

NM-HU-00041

維持形態

Repository Live

PDFを取得

説明

The endogenous mouse Tnfrsf4(Ox40) gene was replaced by human TNFRSF4(OX40) gene. While hOX40(2)(Stock No.NM-HU-00078) mice function similarly to hOX40 mice,for more detailed information please contact our technical advisor.
応用分野:Immunotherapy,cancer research,drug screening

表現型データ

  • Flow cytometry (FACS) analysis data of lymph node T-cells collected from humanized OX40 mice

image.png

Fig 1. Expression of OX40 in the spleen lymphocytes of humanized OX40 mice is detected by FACS.

The spleen lymphocytes of heterozygous humanized OX40 mice were activated by anti-CD3 and anti-CD28 for 48 hours, and then collected for staining. Along with a group undergoing no stimulation, the expression of murine and human OX40 was detected by FACS. The results showed that the active expression of human OX40 can be detected in both activated CD4and CD8+ T lymphocytes collected from heterozygous humanized OX40 mice, and the expression trend of human OX40 and murine Ox40 was similar.

  • In vivo validation in a MC38 tumor-bearing model of humanized OX40 mouse.


  • Case study 1

OX40.png

OX40-2.png

Fig 2. OX40 antibody showed dose-dependent anti-tumor activity in human OX40  knock-in mice bearing MC38 tumors. The OX40 antibody  was obtained from Innoventbio.

  • Case study 2

fig4.png

Fig 3 IBI101 showed dose-dependent anti-tumor activity and  enhanced tumor-specific CD8+ T cell response in human OX40  knock-in mice bearing MC38 tumors. a Tumor growth curve of mice  treated with different doses of IBI101 alone or in combination with  anti-mouse PD-1 antibody. Different doses of IBI101 and anti-mouse PD-1 antibody were administrated as indicated by the arrow heads  after MC38 cells implantation. b Animal body weights were measured during the time course of the experiment. c Mice were injected with h-IgG (10  mg/kg), IBI101 (10  mg/kg), anti-PD-1 (0.5  mg/kg)  alone or IBI101  (10 mg/kg)+anti-PD-1  (0.5 mg/kg) at day 10 and  14 post tumor cell implantation. At day 17, tumor and spleen were  collected and analyzed by flow cytometry for the absolute counts of  the indicated cell subsets in tumor and d proportions of indicated cell  subsets in CD45+ splenocytes. Flow cytometry results showing the  proportions of cytokine-secreting cancer-specific CD8+ and CD4+ T  cells from tumor (e) and spleen (f) (n≥5) (In collaboration with Innoventbio)


あなたも好きかも

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

詳細
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

詳細